CLASS II Drug recall · Reported 31 Jul 2019 · FDA Enforcement Report

Temozolomide Capsules, 250 mg recalled by Deva Holding AS - Cerkezkoy

Deva Holding AS - Cerkezkoy Subesi is recalling Temozolomide Capsules, 250 mg, distributed nationwide in the US. The recall was initiated on 16 Jul 2019 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: A062228, A062227, A062226, A062295, A062294, Exp 08/31/2019; A069325, A069323, Exp 05/31/2020; A072015, Exp 10/31/2020; A076611, A076609, A076608, A076607, Exp 04/30/2021
NDC67877-537, 67877-538, 67877-539, 67877-540, 67877-541, 67877-542
Quantity recalled11472 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1513-2019
FDA event ID
83327
Recalling firm
Deva Holding AS - Cerkezkoy Subesi, Cerkezkoy, N/A
Manufacturer
Ascend Laboratories, LLC
Classification
Class II
Status
Terminated
Recall initiated
16 Jul 2019
FDA classified
23 Jul 2019
Reported
31 Jul 2019
Type
Voluntary: Firm initiated
Customers notified by
E-Mail

Timeline

16 Jul 2019Recall initiated by company
23 Jul 2019Classified by FDA+7 days
31 Jul 2019Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.

Product as listed by the FDA

Temozolomide Capsules, 250 mg, 5-count bottle, Rx only, Manufactured by: Deva Holding A.S., 1 Merkez Mahallesi, Istanbul, Turkey 34303, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-542-07.

Where it was distributed

Nationwide in the USA.

Nationwide

Questions about this recall

Is Temozolomide Capsules, 250 mg recalled?

Yes. Deva Holding AS - Cerkezkoy Subesi recalled Temozolomide Capsules, 250 mg on 16 Jul 2019. The recall is Class II and its status is Terminated. Recall number D-1513-2019.

Why was it recalled?

CGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.

Which lots are affected?

Lot #: A062228, A062227, A062226, A062295, A062294, Exp 08/31/2019; A069325, A069323, Exp 05/31/2020; A072015, Exp 10/31/2020; A076611, A076609, A076608, A076607, Exp 04/30/2021

Where was it sold?

Nationwide in the USA.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Deva Holding AS - Cerkezkoy Subesi

All 6

Other Temozolomide recalls

All 15